Delivery Order 75N98019D00058-75N98020F00001

Award Date 9/18/20
Potential Completion Date 9/26/24
Potential Value $10K
Ultimate Awardee
Irisys, Inc.
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Rockville, MD 20852, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $760,749 firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health, to Societal CDMO San Diego, LLC (doing business as Irisys Inc.). The order is to provide dosage form development, manufacturing, and stability studies of the investigational drug ORC-13661 for a Phase II clinical trial. This delivery order was issued under the NCATS Drug Product Development Studies 2017-2022 indefinite...
This is a delivery order contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business. The $704,621.50 firm-fixed-price contract is for the dosage form development, manufacture, and stability studies of the investigational drug AVE-1625 (drinabant). The work is being performed in San Diego, California. This delivery order is...
This is a delivery order awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Societal Cdmo San Diego, LLC, doing business as Irisys Inc. The $127,330 cost-plus-fixed-fee contract is for special studies and analysis related to chemical and biological agents. The contract has no set-aside designation. Societal Cdmo San Diego is a small disadvantaged business that provides pharmaceutical development, manufacturing, and testing...
Societal Cdmo San Diego, LLC was awarded a $78,600 firm fixed price delivery order against the National Cancer Institute Cooperative Agreement for Cancer Target Discovery and Preclinical Validation Studies master indefinite-delivery/indefinite-quantity contract by the Department of Health and Human Services' National Institutes of Health. Under the delivery order, Societal Cdmo San Diego, LLC will provide metarestin storage and stability testing services for the National Cancer Institute,...
This is a $620,051 delivery order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business. The contract is for the production of TAK-243 injectable for clinical use and study of its shelf-life. Societal CDMO will also develop and manufacture oral and topical dosage forms under this delivery order. This contract is issued...
This federal contract award, valued at $89,418.97, was issued by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), to Societal Cdmo San Diego, LLC, doing business as Irisys Inc. Societal Cdmo San Diego is a small disadvantaged business that specializes in pharmaceutical product development, manufacturing, and testing services for the federal government. The contract is for "SPECIAL...
This federal contract award was issued by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS), to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business and contract development and manufacturing organization (CDMO). The $77,283 task order is for the manufacture of 4-thio-2-deoxycytidine capsules, which are likely being developed for use in...
This is a $17,542 Cost Plus Fixed Fee delivery order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Societal CDMO San Diego, LLC (doing business as Irisys Inc.), a self-certified small disadvantaged business. The contract is for the production and evaluation of the stability of tetrathiomolibdate capsules in a non-GMP study. This award is part of Societal CDMO San Diego's work...
The National Institutes of Health (NIH), an agency of the Department of Health and Human Services, awarded an $11,000 firm fixed price delivery order to Societal Cdmo San Diego, LLC for stability studies required by Good Manufacturing Practices for a finished pharmaceutical product containing mithramycin lyophilized powder for injection. The delivery order was issued against the prime contractor's master indefinite-delivery/indefinite-quantity contract vehicle known as the Drug Formulation and...
This $136,500 firm fixed-price delivery order was awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Societal CDMO San Diego, LLC (doing business as Irisys Inc.). The contract is for the production of 2,500 vials of Cooper Histindinate, a pharmaceutical product likely used in cancer research and development. Societal CDMO San Diego is a small disadvantaged business contract development and manufacturing organization that...

The National Institutes of Health, Office of Logistics and Acquisition Operations awarded a $10,198 firm fixed price delivery order to Societal Cdmo San Diego, LLC under the Drug Formulation and Manufacturing Contracts 2019 indefinite-delivery/indefinite-quantity multiple award contract vehicle. Societal Cdmo San Diego, LLC will perform stability drug testing of decitabine capsules according to Document Number X-QC-013-02 in the statement of work. Irisys, Inc. is the parent company of prime contractor Societal Cdmo San Diego, LLC. Performance will take place in Rockville, Maryland through September 2024. This delivery order supports the National Institutes of Health's efforts to research and develop new drug therapies.

Generated 12/30/23, 12:38 AM